Literature DB >> 10534549

Rheumatic disorders developed after hepatitis B vaccination.

J F Maillefert1, J Sibilia, E Toussirot, E Vignon, J P Eschard, B Lorcerie, R Juvin, N Parchin-Geneste, C Piroth, D Wendling, J L Kuntz, C Tavernier, P Gaudin.   

Abstract

OBJECTIVE: To obtain an overview of rheumatic disorders occurring after hepatitis B vaccination.
METHODS: A questionnaire was sent to rheumatology departments in nine French hospitals. Criteria for entry were rheumatic complaints of 1 week's duration or more, occurrence during the 2 months following hepatitis B vaccination, no previously diagnosed rheumatic disease and no other explanation for the complaints.
RESULTS: Twenty-two patients were included. The observed disorders were as follows: rheumatoid arthritis for six patients; exacerbation of a previously non-diagnosed systemic lupus erythematosus for two; post-vaccinal arthritis for five; polyarthralgia-myalgia for four; suspected or biopsy-proved vasculitis for three; miscellaneous for two.
CONCLUSIONS: Hepatitis B vaccine might be followed by various rheumatic conditions and might trigger the onset of underlying inflammatory or autoimmune rheumatic diseases. However, a causal relationship between hepatitis B vaccination and the observed rheumatic manifestations cannot be easily established. Further epidemiological studies are needed to establish whether hepatitis B vaccination is associated or not with an incidence of rheumatic disorders higher than normal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534549     DOI: 10.1093/rheumatology/38.10.978

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  27 in total

1.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Systemic vasculitis: a dual diagnosis?

Authors:  Eliza Gil; Pamela Lutalo; David D'Cruz
Journal:  BMJ Case Rep       Date:  2011-12-02

3.  Vaccination and rheumatoid arthritis.

Authors:  J Sibilia; J F Maillefert
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

Review 4.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 7.  An update on drug-induced arthritis.

Authors:  Marwan H Adwan
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

8.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.

Authors:  I Fomin; D Caspi; V Levy; N Varsano; Y Shalev; D Paran; D Levartovsky; I Litinsky; I Kaufman; I Wigler; E Mendelson; O Elkayam
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 9.  Hepatitis B virus (HBV) and autoimmune disease.

Authors:  Ram Maya; M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

10.  Joint symptoms and diseases associated with moisture damage in a health center.

Authors:  R A Luosujärvi; T M Husman; M Seuri; M A Pietikäinen; P Pollari; J Pelkonen; H T Hujakka; O A Kaipiainen-Seppänen; K Aho
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.